Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer

Port J Card Thorac Vasc Surg. 2023 Oct 11;30(3):9-11. doi: 10.48729/pjctvs.381.
No abstract available

Publication types

  • Letter

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Mutation

Substances

  • ErbB Receptors
  • EGFR protein, human